- Home
- BMR vs OTLK Comparison
BMR vs OTLK Comparison
Compare BMR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMR
- OTLK
- Stock Information
- Founded
- BMR 2009
- OTLK 2010
- Country
- BMR Israel
- OTLK United States
- Employees
- BMR N/A
- OTLK N/A
- Industry
- BMR Computer Software: Prepackaged Software
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMR Technology
- OTLK Health Care
- Exchange
- BMR Nasdaq
- OTLK Nasdaq
- Market Cap
- BMR 59.3M
- OTLK 48.3M
- IPO Year
- BMR 2023
- OTLK 2016
- Fundamental
- Price
- BMR $3.19
- OTLK $1.71
- Analyst Decision
- BMR
- OTLK Strong Buy
- Analyst Count
- BMR 0
- OTLK 5
- Target Price
- BMR N/A
- OTLK $9.60
- AVG Volume (30 Days)
- BMR 1.0M
- OTLK 823.9K
- Earning Date
- BMR 08-05-2025
- OTLK 08-13-2025
- Dividend Yield
- BMR N/A
- OTLK N/A
- EPS Growth
- BMR N/A
- OTLK N/A
- EPS
- BMR N/A
- OTLK 0.83
- Revenue
- BMR $3,064,000.00
- OTLK N/A
- Revenue This Year
- BMR $21.21
- OTLK N/A
- Revenue Next Year
- BMR N/A
- OTLK $379.84
- P/E Ratio
- BMR N/A
- OTLK $2.06
- Revenue Growth
- BMR 5.33
- OTLK N/A
- 52 Week Low
- BMR $1.86
- OTLK $0.87
- 52 Week High
- BMR $6.59
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- BMR 51.92
- OTLK 46.49
- Support Level
- BMR $2.88
- OTLK $1.65
- Resistance Level
- BMR $4.32
- OTLK $1.97
- Average True Range (ATR)
- BMR 0.31
- OTLK 0.12
- MACD
- BMR -0.04
- OTLK -0.03
- Stochastic Oscillator
- BMR 20.19
- OTLK 10.94
About BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.